Compare GSK plc (GSK) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Materials Select Sector SPDR Fund — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: GSK plc is far larger — about 11.9× Materials Select Sector SPDR Fund's market cap, and GSK plc pays a 3.9% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| GSK | XLB | |
|---|---|---|
Market Cap | $91.88B | $7.73B |
Volume | 7,730,529 | 13,681,146 |
Sector | Health | — |
52-Week High | $61.18 | $53.67 |
52-Week Low | $43.24 | $42.23 |
Typical Hold Time | 93 Days | 70 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
XLB, the Materials Select Sector SPDR ETF, trades at $49.27, up 0.59% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF's portfolio is heavily concentrated in chemicals (49% of assets), and recent analysis suggests limited upside after a sector rebound, with construction materials moderately overvalued and chemicals showing weak value-quality scores.
Outlook remains cautious due to cyclical pressures and high concentration risk, though long-term infrastructure and manufacturing trends offer support. Investors face headwinds from sector volatility and priced-in recovery, but the ETF provides low-cost exposure to large-cap U.S. materials stocks for those seeking broad sector allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
